Prescription drug · NDA AUTHORIZED GENERIC
Metoclopramide NDC 67296-2213
Metoclopramide hydrochloride 5 mg/1 · Tablet · Oral · Redpharm Drug
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 67296-2213-1 | 67296221301 | 15 TABLET in 1 BOTTLE, PLASTIC (67296-2213-1)Marketed from Dec 13, 2021 |
How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Metoclopramide
- Generic name (nonproprietary)
- metoclopramide
- Active ingredients
- Metoclopramide hydrochloride — 5 mg/1
- Dosage form
- Tablet
- Route
- Oral
- Labeler
- Redpharm Drug
- Product type
- Prescription drug
- Marketing category
- NDA authorized genericApplication NDA 017854
- Marketing start
- Listing expires
- Other FDA classes
- Dopamine D2 Antagonists (Mechanism)
- Identifiers
- Product ID 67296-2213_49eb7254-b7f9-6119-e063-6394a90aaf3dSPL ID 49eb7254-b7f9-6119-e063-6394a90aaf3dSPL set ID 49eb807b-fa34-3d84-e063-6394a90acfcfRxCUI 311668UNII W1792A2RVDUPC 0362559296014, 0362559295017
- Pharmacologic class
- Dopamine-2 Receptor Antagonist
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N467296221301followed by a unit qualifier and the quantityPackage 67296-2213-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective . This label includes a boxed warning.
Indications (excerpt from the label)
Metoclopramide tablets are indicated for the: Treatment for 4 to 12 weeks of symptomatic, documented gastroesophageal reflux in adults who fail to respond to conventional therapy. Relief of symptoms in adults with acute and recurrent diabetic gastroparesis. Limitations of Use : Metoclopramide tablets are not recommended for use in pediatric patients due to the risk of developing tardive dyskinesia (TD) and other extrapyramidal symptoms as well as the risk of methemoglobinemia in neonates [see Use in Specific Populations ( 8.4 )]. Metoclopramide tablets are indicated for the: Treatment for 4 to 12 weeks of symptomatic, documented gastroesophageal reflux in adults who fail to respond to conven…
Excerpt only. Read the full label for complete information.
Other NDCs under NDA 017854
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Reglanmetoclopramide hydrochloride | Metoclopramide hydrochloride 10 mg/1 | TabletOral | ANI Pharmaceuticals, Inc. | 62559-166 |
| Reglanmetoclopramide hydrochloride | Metoclopramide hydrochloride 5 mg/1 | TabletOral | ANI Pharmaceuticals, Inc. | 62559-165 |
| Metoclopramide | Metoclopramide hydrochloride 5 mg/1 | TabletOral | ANI Pharmaceuticals, Inc. | 62559-295 |
| Metoclopramide | Metoclopramide hydrochloride 10 mg/1 | TabletOral | ANI Pharmaceuticals, Inc. | 62559-296 |
| Metoclopramide | Metoclopramide hydrochloride 10 mg/1 | TabletOral | REMEDYREPACK INC. | 70518-4541 |